Company Overview and News

 
Dyadic International's (DYAI) CEO Mark Emalfarb on Q1 2018 Results - Earnings Call Transcript

2018-05-14 seekingalpha
Good afternoon, ladies and gentlemen, and thank you for holding. Welcome to Dyadic International's First Quarter 2018 Financial Results Conference Call. Now, all participants are in a listen-only mode. My name is Dana and I'll be your conference coordinator today. As a reminder, please note that this call is being recorded.

1
Regeneron Pharmaceuticals (REGN) Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Welcome to the Regeneron Pharmaceuticals First Quarter 2018 Earnings Conference Call. My name is Jason and I will be your operator. At this time all participants will be in a listen-only mode. Later, we will have a question-and-answer session. Also, please note this conference is being recorded.

 
The Drug Committee of Ministry of Health, Labour and Welfare in Japan has accepted a 2-year extension of market exclusivity of Lexapro®

2018-04-27 globenewswire
Valby, Denmark, 27 April 2018 - H. Lundbeck A/S (Lundbeck) today announced that Lexapro® (escitalopram oxalate), which is distributed by Mochida Pharmaceutical Co., Ltd. (Mochida) and Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) in Japan, is expected to receive a final confirmation of the extension of the eight-year market exclusivity by the Japanese Ministry of Health, Labour and Welfare (MHLW).

 
Det japanske Sundheds-, arbejds- og socialministerium (MHLW) accepterer en forlængelse af markedseksklusivitet på to år for Lexapro®

2018-04-27 globenewswire
Valby, Danmark, 27. april 2018 - H. Lundbeck A/S (Lundbeck) annoncerede i dag, at Lexapro® (escitalopram oxalat), som markedsføres af Mochida Pharmaceutical Co., Ltd. (Mochida) og Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) i Japan, forventes at modtage endelig bekræftelse på en forlængelse af den otteårige markedseksklusivitet af det japanske Sundheds-, arbejds- og socialministerium (Ministry of Health, Labour and Welfare – herefter MHLW).

 
Neuraltus Weighs Future of Lead Candidate NP001 After Failure in Phase II ALS Trial

2018-04-26 genengnews
Neuraltus Pharmaceuticals said today it is weighing if, and how, it plans to continue developing its lead candidate NP001 after it failed a Phase II confirmatory study in ALS patients with elevated levels of systemic inflammation—a review that makes the drug unlikely to be the third approved treatment for the disease any time soon, if ever.

 
Amgen Backs Launch of Golden Ticket Winning ALS Company QurAlis

2018-04-05 biospace
After winning Amgen’s coveted 2017 Golden Ticket in December 2017 startup company QurAlis officially launched with financial backing from Amgen Ventures with a mission to develop a cure for Amyotrophic Lateral Sclerosis (ALS).

 
Dyadic International's (DYAI) CEO Mark Emalfarb on Q4 2017 Results - Earnings Call Transcript

2018-03-28 seekingalpha
Good afternoon, ladies and gentlemen. Thank you for holding. Welcome to Dyadic International’s 2017 Year-End Financial Results Conference Call. At this time all participants are in a listen-only mode. My name is Catherine, I will be your conference coordinator for today. As a reminder, please note that this call is being recorded.

 
Dyadic International Announces 2017 Year End Results and Recent Developments

2018-03-27 globenewswire
JUPITER, Fla., March 27, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying our proprietary C1 gene expression platform to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the year ended December 31, 2017, and recent company developments.

 
Akebia Announces $85M Public Offering

2018-03-23 biospace
Cambridge, Massachusetts-based Akebia Therapeutics announced plans to offer and sell about $85 million of its common stock in an underwritten public offering.

 
VIVUS Reports Fourth Quarter 2017 Financial Results

2018-03-13 marketwired
CAMPBELL, CA--(Marketwired - March 13, 2018) - VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter and year ended December 31, 2017 and provided a business update.

 
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q4 2017 Results - Earnings Call Transcript

2018-02-14 seekingalpha
Good day, everyone, and welcome to Neurocrine Biosciences’ Reports Fourth Quarter and Year End 2017 Results. [Operator Instructions] Please note, today's call is being recorded. [Operator Instructions]

 
Mitsubishi Tanabe Pharma Corp. ADR 2017 Q3 - Results - Earnings Call Slides

2018-02-05 seekingalpha
The following slide deck was published by Mitsubishi Tanabe Pharma Corp. ADR in conjunction with their 2017 Q3 earnings call.

1
Mobileye deal boosts Israeli high-tech exits to $23 bln in 2017

2018-01-03 reuters
TEL AVIV (Reuters) - Israeli high-tech acquisitions and initial public offering activity soared to $23 billion in 2017 from $10 billion in 2016 due to the $15.3 billion purchase of Mobileye by Intel Corp (INTC.O), data published on Wednesday showed.

7
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update

2017-11-21 seekingalpha
Halvorsen's 13F portfolio value increased from $14.85B to $15.44B. The number of positions increased from 53 to 59.

 
Akebia Therapeutics Is A Buy With The Recent Stock Price Pullback

2017-11-10 seekingalpha
This was written for our subscribers last week, and since then the stock is down 15% on EPS loss.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 606813202